Clinical Trial Update: Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC) [Phase 1]

View source ↗

Summary

Phase 1 trial update investigating enzalutamide and niraparib for metastatic castration-resistant prostate cancer (CRPC) has been terminated with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• Niraparib (Niraparib)

Snippet

Sponsor: Paul Mathew, MD | Conditions: Metastatic Prostate Cancer | Phase 1 | Status: TERMINATED | Results posted: 2019-10-21